| SEC F | Form 4 |
|-------|--------|
|-------|--------|

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

| OMB Number: | 3235-0287 | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|
| Estimated average burden | | | | | | | |
| hours per response: | 0.5 | | | | | | |

| Instruction 1(b). | | Filec | d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | | | |
|---------------------------------|----------------------------------|----------------|--|------------------------|---|--|
| 1. Name and Addres | ss of Reporting Pers <u>h</u> | on* | 2. Issuer Name and Ticker or Trading Symbol <u>Unum Therapeutics Inc.</u> [UMRX] | | tionship of Reporting all applicable) Director Officer (give title | Person(s) to Issuer 10% Owner Other (specify |
| | | | 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2019 | | below) Chief Scien | below) tific Officer |
| (Street) CAMBRIDGE (City) | MA (State) | 02140 (Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indiv Line) X | Form filed by One | Filing (Check Applicable Reporting Person e than One Reporting |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| | | • | | <u> </u> | , | | | | | |
|---------------------------------|--|---|------------------------------|----------|---|---------------|-------|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transa Code (8) | ction | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported | Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (11150.4) |

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|---|--|---|------------------------------|---|--------|-----|--|--------------------|---|--|---|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option (Right to Buy) | \$4.36 | 03/01/2019 | | A | | 69,700 | | (1) | 03/01/2029 | Common Stock | 69,700 | \$0.00 | 69,700 | D | |

Explanation of Responses:

1. 25% of the shares vests on March 1, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Persons continuous service with the Issuer.

<u>/s/ Amoli Pandya, as Attorney-</u> <u>in-Fact</u> 04/1

04/11/2019

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP